linezolid + vancomycin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Febrile Neutropenia
Conditions
Febrile Neutropenia
Trial Timeline
Nov 1, 2001 → Nov 1, 2002
NCT ID
NCT00035425About linezolid + vancomycin
linezolid + vancomycin is a phase 3 stage product being developed by Pfizer for Febrile Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00035425. Target conditions include Febrile Neutropenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01561469 | Pre-clinical | Completed |
| NCT00087490 | Approved | Completed |
| NCT00035425 | Phase 3 | Completed |
Competing Products
8 competing products in Febrile Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 85 |
| Ceftolozane-tazobactam IV | Merck | Approved | 85 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 77 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 84 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 22 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 74 |